Clients News • MC Services corporate website
5522
paged,page-template-default,page,page-id-5522,paged-3,page-paged-3,bridge-core-2.1.4,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-20.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-6.7.0,vc_responsive

CLIENT NEWS

 

 

  • InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19
    www.inflarx.de
  • Abivax receives FDA agreement on pediatric development plan with obefazimod in IBD
    www.abivax.com
  • Mainz Biomed Enrolls First Patient in eAArly DETECT Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert
    www.mainzbiomed.com
  • Rentschler Biopharma awarded Chiesi Supplier Award
    www.rentschler-biopharma.com
  • Heidelberg Pharma Signs Research and Exclusive Option Agreement with Binghamton University on Immunostimulatory Technology Platform
    www.heidelberg-pharma.com
  • Carbios publishes first Sustainability Report and underscores commitment to circularity and environmental responsibilities
    www.carbios.com
  • ABIVAX TO ATTEND THE J.P. MORGAN 41ST ANNUAL HEALTHCARE CONFERENCE
    www.abivax.com
  • invIOs to present at Biotech Showcase
    www.invios.com
  • Apogenix Enrolls First Patients in Pivotal Phase III Trial for the Treatment of Hospitalized COVID-19 Patients with Asunercept
    www.apogenix.com
  • Spexis announces promising pre-clinical data with balixafortide in combination with various therapies on the market for treating B-cell lymphomas
    www.spexisbio.com